Pharma BD Deal Intelligence
ArQule acquired Camitro Corporation, an in silico ADME/Tox modeling company, in a stock-and-cash merger valued at ~$95M (announced; ~$85M at close: 3.4M ArQule shares + $1.7M cash). The deal integrated predictive ADMET into ArQule's parallel-synthesis discovery engine as CEO Stephen Hill pivoted from chemistry services toward drug discovery; ArQule ultimately could not commercialize the technology, leading to site closures and layoffs.